相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of Epidermal Growth Factor Receptor Inhibitor-Induced Dermatologic Toxicities on Quality of Life
Smita S. Joshi et al.
CANCER (2010)
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
Mario E. Lacouture et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia
T. Eames et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2010)
Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy
R. E. Eilers et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists
Jessica C. Hassel et al.
ONKOLOGIE (2010)
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
Mario E. Lacouture et al.
SUPPORTIVE CARE IN CANCER (2010)
Evidence-Based Treatment Options for the Management of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
Eng Hooi Tan et al.
ANNALS OF PHARMACOTHERAPY (2009)
Analysis of dermatologic events in patients with cancer treated with lapatinib
M. E. Lacouture et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors
A. Osio et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Increased Risk of High-Grade Dermatologic Toxicities With Radiation Plus Epidermal Growth Factor Receptor Inhibitor Therapy
Ajay Tejwani et al.
CANCER (2009)
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer
S. Sehdev et al.
CURRENT ONCOLOGY (2009)
Cetuximab Therapy of Metastasizing Cutaneous Squamous Cell Carcinoma in a Patient with Severe Recessive Dystrophic Epidermolysis Bullosa
Andreas W. Arnold et al.
DERMATOLOGY (2009)
Skin toxicities of targeted therapies
Siegfried Segaert et al.
EUROPEAN JOURNAL OF CANCER (2009)
Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers
Andrew N. Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption
Alon Scope et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147
Aminah Jatoi et al.
ONCOLOGY (2009)
Skin toxicities associated with epidermal growth factor receptor inhibitors
Tianhong Li et al.
TARGETED ONCOLOGY (2009)
Scarring Alopecia Associated With Use of the Epidermal Growth Factor Receptor Inhibitor Gefitinib
Jeffrey C. Donovan et al.
ARCHIVES OF DERMATOLOGY (2008)
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes - Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
Aminah Jatoi et al.
CANCER (2008)
Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Paul Wheatley-Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Is there room for improvement in adverse event reporting in the era of targeted therapies?
Maureen Edgerly et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2
Qin Ryan et al.
ONCOLOGIST (2008)
Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
Bernhard Berger et al.
RADIATION ONCOLOGY (2008)
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption
Alon Scope et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Patient-reported outcomes and the evolution of adverse event reporting in oncology
Andy Trotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Ocular toxicities of epidermal growth factor receptor inhibitors and their management
Surendra Basti
CANCER NURSING (2007)
Temporal dependence of the effect of radiation on erlotinib-induced skin rash
Mario E. Lacouture et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib
Minnelly Luu et al.
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE (2007)
Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management
Jenny C. Hu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results
Susan L. Boone et al.
ONCOLOGY (2007)
Nail toxicity associated with epidermal growth factor receptor inhibitor therapy
Lindy P. Fox
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients
P. Bossi et al.
ANNALS OF ONCOLOGY (2007)
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management
Thomas J. Lynch et al.
ONCOLOGIST (2007)
Erlotinib-associated trichomegaly
Katherine Lane et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2007)
FDA drug approval summary: Panitumumab (Vectibix (TM))
Ruthann M. Giusti et al.
ONCOLOGIST (2007)
Mechanisms of cutaneous toxicities to EGFR inhibitors
Mario E. Lacouture
NATURE REVIEWS CANCER (2006)
Description and management of cutaneous side effects during cetuximab or erlotinib treatments:: A prospective study of 30 patients
Esther Roe et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
Julia E. Graves et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Effects of smoking on the pharmacokinetics of erlotinib
M Hamilton et al.
CLINICAL CANCER RESEARCH (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab
KY Suh et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
HER1/EGFR inhibitor-associated rash:: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
R Pérez-Soler et al.
ONCOLOGIST (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
S Segaert et al.
ANNALS OF ONCOLOGY (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
EK Rowinsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours
W Jacot et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor
MW Lee et al.
ACTA DERMATO-VENEREOLOGICA (2004)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
R van Doorn et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
Getting under the skin of epidermal morphogenesis
E Fuchs et al.
NATURE REVIEWS GENETICS (2002)
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
J Albanell et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
KJ Busam et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)
分享论文
